Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche to Acquire Seragon Pharmaceuticals

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.

Roche announced that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California, USA. With this acquisition, Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs), for the potential treatment of hormone receptor-positive breast cancer.

“This year, breast cancer will claim the lives of nearly 40,000 women in the United States, and up to half of these women will have a disease that is driven by the estrogen receptor,” said Richard Scheller, Ph.D., Executive Vice President and Head of Genentech Research and Early Development. “We believe these investigational oral SERDs could one day redefine the standard of care for hormone receptor-positive breast cancer.”

Under the terms of the agreement, Genentech will make an upfront cash payment of $725 million, plus additional contingent payments of up to $1 billion based on achievement of certain predetermined milestones. The closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in the third quarter of 2014. Once the transaction is completed, Seragon’s portfolio will be integrated into Genentech Research and Early Development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche’s MabThera SC Receives Approval in Europe
Company has announced that the EC has approved the SC formulation of MabThera® for people with previously untreated chronic lymphocytic leukaemia (CLL).
Friday, June 03, 2016
FDA Grants Roche’s Cancer Immunotherapy Tecentriq Accelerated Approval
Company has announced that the U.S. FDA has granted accelerated approval to Tecentriq® for the treatment of people with a specific type of advanced bladder cancer.
Friday, May 20, 2016
Blueprint Medicine, Roche Collaborate
Collaboration combines blueprint medicines' proprietary drug discovery platform and immunokinase expertise with Roche's cancer immunotherapy expertise.
Wednesday, March 16, 2016
Tensha Therapeutics to be Acquired by Roche
Tensha Therapeutics, a privately-held company based in Cambridge, MA, has announced it will be acquired by Roche.
Tuesday, January 12, 2016
Roche to Restructure its Manufacturing Network for Small Molecules
Changes to address shift to new generation of medicines.
Tuesday, November 24, 2015
Roche Receives FDA Approval for Viral Load Tests and Cobas 6800/8800 Systems
Roche has received FDA approval for the cobas® HBV and cobas® HCV viral load tests, the first assays approved by the FDA for use on the cobas® 6800 and cobas® 8800 Systems.
Sunday, October 18, 2015
Roche Launches the cobas EGFR Mutation Test v2
New test is the first to be validated for use of either sample type in a single test.
Wednesday, October 14, 2015
Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
US FDA Grants Therapy Designation for Roche’s Investigational Medicine ACE910
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of haemophilia A.
Tuesday, September 08, 2015
Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche Acquires GeneWEAVE to Strengthen Offerings in Microbiology Diagnostics
GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria.
Friday, August 14, 2015
Roche's Investigational Immunotherapy Shrank Bladder Cancer Tumors in Pivotal Study
The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.
Tuesday, July 14, 2015
Roche Acquires Ariosa Diagnostics
Acquisition will see Roche enter the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets.
Wednesday, December 03, 2014
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!